Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $6.05, for a total value of $90,750.00. Following the completion of the transaction, the insider now owns 944,873 shares of the company’s stock, valued at approximately $5,716,481.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Estuardo Aguilar-Cordova also recently made the following trade(s):

• On Monday, October 14th, Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock. The shares were sold at an average price of $6.02, for a total value of $90,300.00.
• On Thursday, October 3rd, Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock. The stock was sold at an average price of $6.85, for a total transaction of $12,330.00.

Candel Therapeutics Trading Down 0.8 %

CADL opened at $5.95 on Wednesday. Candel Therapeutics, Inc. has a 1-year low of $0.66 and a 1-year high of $14.30. The stock has a market capitalization of $177.05 million, a PE ratio of -4.65 and a beta of -0.95. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average price of $6.31 and a two-hundred day moving average price of $6.81.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. As a group, equities analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CADL. Point72 DIFC Ltd bought a new position in Candel Therapeutics in the second quarter valued at about $31,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Candel Therapeutics during the 2nd quarter worth approximately $162,000. Rhumbline Advisers acquired a new position in Candel Therapeutics in the second quarter valued at approximately $143,000. Finally, Bank of New York Mellon Corp bought a new position in Candel Therapeutics in the second quarter valued at approximately $338,000. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.